By visiting our website or using services provided by Sai Life Sciences, you are accepting the practices described in the Privacy Policy.

We also use cookies on our websites. Cookies allow us to give you the best browsing experience and help us to understand how you use our site. You can disable cookies but parts of our website may not work. By continuing to use this website, you agree that we may store and access cookies on your device.

By clicking “I Accept”, you confirm that you are above the age of 16, that you have read and understood the Cookies Usage and the Privacy Policy, and that you agree to the collection, use and processing of your Personal Information by Sai Life in accordance with said policies.

I accept

Stay up to date with our newsletter

Get in touch!

To explore career opportunities with Sai Life Sciences, share your CV here.

Lets start the conversation!

Sign up to our newsletter

Thank you!
We will be in touch shortly.

2024.10.28

Advanced manufacturing facility at Sai Life Sciences, showcasing state-of-the-art equipment and quality control, featured in a blog post about receiving Establishment Inspection Reports (EIRs) from the USFDA.

Sai Life Sciences receives EIRs from USFDA for India R&D & Manufacturing facilities

Sai Life Sciences, the fastest-growing Indian Contract Research, Development and Manufacturing Organization (CRDMO)[1], announced that it has received Establishment Inspection Reports (EIR) from the US Food and Drug Administration (USFDA) for its R&D (Unit II, Hyderabad), and Manufacturing (Unit IV, Bidar) sites in India.

The General Good Manufacturing Practices (GMP) audit was conducted at the integrated R&D campus (Unit II) in April 2024, while the pre-approval inspection (PAI) & General GMP audit was conducted at the Manufacturing facility (Unit IV) in Bidar in June 2024.

Making the announcement, Krishna Kanumuri, CEO & Managing Director of Sai Life Sciences, said, “These audit outcomes reflect Sai Life Sciences’ commitment to maintaining the highest standards of quality and compliance across its R&D and manufacturing facilities. It demonstrates the company’s robust quality systems and its readiness to support the supply of high-quality pharmaceutical products to global markets."

[1] Among listed Indian peers in terms of revenue CAGR as well as EBITDA CAGR over FY22-24.

Share article

More News

2026.01.28

Mabtech and Sai Life Sciences Announce Strategic Collaboration to Advance Immunology Research with EYRA Platform at Sai Boston Site

Mabtech, a global life science tools company specializing in advanced immunoassays, and Sai Life Sciences, a leading integrated Contract Research, Development, and Manufacturing Organization (CRDMO), today announced a strategic collaboration that establishes Sai’s Boston laboratory as a co-marketed US execution and demonstration hub for the Mabtech EYRA™ platform. Under this collaboration, Mabtech and Sai will […]
Read more

2026.01.12

Sai Life Sciences laboratories achieve Green Lab Certification

Sai Life Sciences has achieved Green Lab Certification for two PR&D laboratories and two Medicinal Chemistry laboratories under the My Green Lab (MGL) framework, with a compliance score of over 98%.The certification reflects the company’s systematic efforts to integrate sustainability into daily laboratory operations, with measurable reductions in energy consumption, water usage, waste generation, and […]
Read more

2025.12.19

Sai Life Sciences Releases Sustainability Report 2025

Sai Life Sciences Limited (BSE: 544306 | NSE: SAILIFE), one of India’s fastest-growing Contract Research, Development, and Manufacturing Organizations (CRDMO), today announced the release of its Sustainability Report for 2024–25. Aligned with the Global Reporting Initiative (GRI) Universal Standards 2021 and the Sustainability Accounting Standards Board (SASB) standards, this sixth edition is presented under the […]
Read more

2025.12.15

Pushing Boundaries in Organic Chemistry: IISc Prof. Santanu Mukherjee at Sai Life Sciences

As part of Sai Life Sciences’ ongoing initiative to foster meaningful scientific engagement through interactions with distinguished researchers, Prof. Santanu Mukherjee, Professor in the Department of Organic Chemistry at IISc Bangalore, visited our Integrated R&D campus for a full-day programme of knowledge exchange. He delivered an insightful masterclass on his group’s work in enantioselective desymmetrization—a […]
Read more

2025.11.27

India is evolving from being a tactical supplier to a strategic partner to global pharma

Krishna Kanumuri, MD & CEO of Sai Life Sciences, was recently interviewed by Pharmaceutical Executive for its feature on next-generation CDMOs. In the interview, he shares insights on how Indian CDMOs are evolving from tactical suppliers to strategic partners, the shifting global supply-chain landscape, and how Sai Life Sciences is preparing for the opportunities and […]
Read more